Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPK 005
- Development stage
- Preclinical
- Lead developer
- EPIK Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous, Sublingual, Topical
01
Overview
EPK 005 is a preclinical-stage small molecule combination therapy under development by EPIK Biosciences. Rooted in the company's proprietary platform focused on NMDA receptor modulation, EPK 005 is a ketamine- and/or dextromethorphan (DXM)-based synergistic combination designed to treat neuropsychiatric and pain disorders. The candidate is being investigated for the treatment of depression, anxiety disorders, opioid use disorder, post-traumatic stress disorder (PTSD), and chronic and severe pain. By combining NMDA receptor antagonists with other synergistic active ingredients, EPIK Biosciences aims to enhance therapeutic efficacy, durability, and safety while enabling potential at-home administration.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on EPK 005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPK 005.